TriSalus Life Sciences【TLSI】銘柄情報

TriSalus Life Sciences Inc (TLSI) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

3.17

( -3.94% )

買値

3.16

売値

3.50

出来高

304,401

3.16 日の範囲 3.33

2.20 52 週間の範囲 7.95

時価総額

194.69M

前日終値

3.30

始値

3.29

時刻

3.27

最終取引時間

財務取引量

US$ 985,621

VWAP

3.2379

平均取引量 (3 か月)

US$ 364,941

発行済株式数

61,416,535

配当利回り

PER

-2.62

1 株当たり利益 (EPS)

-1.3

歳入

44.88M

純利益

-27.31M

TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug D... TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado. 詳細を表示

セクター

Healthcare

業界

Medical Equipment & Supplies

ウェブサイト

trisaluslifesci.com

本社

Westminster, United States

設立

2026

TriSalus Life Sciences Inc is listed in the Healthcare sector of the ナスダック市場 with ticker TLSI. The last closing price for TriSalus Life Sciences was US$3.30. Over the last year, TriSalus Life Sciences shares have traded in a share price range of US$ 2.20 to US$ 7.95.

TriSalus Life Sciences currently has 61,416,535 shares in issue. The market capitalisation of TriSalus Life Sciences is US$194.69 million. TriSalus Life Sciences has a price to earnings ratio (PE ratio) of -2.62.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

TriSalus Reports Q3 2024 Financial Results and Provides Business Update

– Reported Q3 and nine-month revenues of $7.3 million and $21.2 million respectively, up 42% and 66% year-over-year – Provided 2025 guidance with...

TriSalus Life Sciences® Forms Strategic Partnership with Geo-Med, LLC to Expand Access of the TriNav® Infusion System to U.S. Veterans with Liver Cancer

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients...

TriSalus Life Sciences Launches TriNav® LV Infusion System and TriGuide™ Guiding Catheters, Expanding Portfolio of PEDD™ Devices for Improved Tumor Treatment

TriSalus Life Sciences® Inc. ("TriSalus" or the "Company") (Nasdaq: TLSI), a leader in oncology innovations integrating advanced delivery...

TriSalus Life Sciences to Host Third Quarter 2024 Financial Results Conference Call

Call Scheduled for Thursday, November 14, 2024, at 9:00 a.m. ET TriSalus Life Sciences® Inc., (Nasdaq: TLSI), an oncology company dedicated to...

TriSalus Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with...

TriSalus Life Sciences Announces Appointment of Riad Salem, M.D., to its Scientific Advisory Board

TriSalus Life Sciences® Inc. (“TriSalus” or the “Company”) (Nasdaq: TLSI), an oncology company dedicated to enhancing outcomes for patients with...

TriSalus Announces Journal of Vascular and Interventional Radiology Publication of Data that Demonstrate Improved Therapeutic Delivery of Glass Microspheres to Solid Tumors With PEDD™ Method via the TriNav® Infusion System

Pressure enabled drug deliver (PEDD) method significantly increased penetration of glass microspheres into porcine liver tumors (117%; p=0.004...

TriSalus Reports Q2 2024 Financial Results and Business Update

Reported revenues of $7.4 million in Q2 2024 and $13.8 million for six months ended June 30, 2024, up 60% and 82%, respectively, compared to...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.08	-2.46153846154	3.25	3.68	3.0504	258217	3.3988764	CS
4	-1.25	-28.2805429864	4.42	4.73	2.2	825921	2.87059682	CS
12	-0.96	-23.2445520581	4.13	4.8499	2.2	371035	3.2225366	CS
26	-3.615	-53.2792925571	6.785	7.95	2.2	273816	4.1789934	CS
52	-1.94	-37.9647749511	5.11	7.95	2.2	195058	4.43402233	CS
156	-10.63	-77.0289855072	13.8	16.24	2.2	99526	5.01164798	CS
260	-10.63	-77.0289855072	13.8	16.24	2.2	99526	5.01164798	CS